Back to News
Jan 7, 2026 4:00 PM

Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial

Jazz Pharmaceuticals plcĀ (NASDAQ:JAZZ) on Tuesday shared efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial of Ziihera (zanidatamab-hrii) for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).

GEA includes cancers of the stomach, gastroesophageal junction, and esophagus.

In November 2025, Jazz Pharmaceuticals and its partners Zymeworks Inc. (NASDAQ:ZYME) and BeOne Medicines Inc. (NASDAQ:ONC) announced topline results from the Phase 3 HERIZON-GEA-01 trial.

The trial evaluated Ziihera in combination with chemotherapy, with or without BeOne’s Tevimbra (tislelizumab), as first-line treatment.

The data will be presented at the 2026 ASCO Gastrointestinal Cancers Symposium ...